Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29686294
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Development of new method to enrich human iPSC-derived renal progenitors using
cell surface markers
#MMPMID29686294
Hoshina A
; Kawamoto T
; Sueta SI
; Mae SI
; Araoka T
; Tanaka H
; Sato Y
; Yamagishi Y
; Osafune K
Sci Rep
2018[Apr]; 8
(1
): 6375
PMID29686294
show ga
Cell therapy using renal progenitors differentiated from human embryonic stem
cells (hESCs) or induced pluripotent stem cells (hiPSCs) has the potential to
significantly reduce the number of patients receiving dialysis therapy. However,
the differentiation cultures may contain undifferentiated or undesired cell types
that cause unwanted side effects, such as neoplastic formation, when transplanted
into a body. Moreover, the hESCs/iPSCs are often genetically modified in order to
isolate the derived renal progenitors, hampering clinical applications. To
establish an isolation method for renal progenitors induced from hESCs/iPSCs
without genetic modifications, we screened antibodies against cell surface
markers. We identified the combination of four markers,
CD9(-)CD140a(+)CD140b(+)CD271(+), which could enrich OSR1(+)SIX2(+) renal
progenitors. Furthermore, these isolated cells ameliorated renal injury in an
acute kidney injury (AKI) mouse model when used for cell therapy. These cells
could contribute to the development of hiPSC-based cell therapy and disease
modeling against kidney diseases.
free
free
free
